Memory Stem T-Cell Therapy for PML via Inhibitory Receptor Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Progressive Multifocal Leukoencephalitis (PML) caused by polyomavirus JC lack effective and sustained immune responses, as existing therapies rely on immune recovery which can be prolonged and ineffective during severe immunosuppression.
Innovation Solution
A novel T-cell therapy using memory stem T-cells (Tscm) negatively selected for inhibitory receptors, such as PD1 and TIGIT, which are expanded and differentiated ex vivo to generate antigen-specific cytotoxic effectors against viral antigens, bypassing functional inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional T cell therapy is used for PML patients, then treatment approach is provided, but immune response is prolonged and ineffective due to severe immunosuppression
Solution Approach 1:
The patent changes the functional parameters of T cells by selectively expanding memory stem T cells (Tscm) that express low levels of inhibitory receptors (PD-1, LAG-3, TIGIT, TIM-3) compared to conventional therapy that uses standard T cell populations. This parameter change in receptor expression levels enables the T cells to maintain functionality despite immunosuppression, resolving the contradiction between providing treatment and achieving effective immune response.
Solution Approach 2:
The patent performs preliminary selection and expansion of Tscm cells ex vivo before administration to patients. By pre-enriching for T cells with low inhibitory receptor expression and activating them with viral antigens before therapy, the system prepares highly functional T cells in advance, reducing the time required for effective immune response in vivo compared to conventional approaches that rely on spontaneous immune recovery.
2Reliability
If memory stem T cells with low inhibitory receptor expression are selected, then T cell functionality and proliferation are enhanced, but cell selection and preparation process becomes more complex
Solution Approach 1:
The patent uses fluorescently labeled antibodies that bind to inhibitory receptors as proxies to identify and sort T cells with low receptor expression. Instead of directly measuring functional properties, the method copies the information about receptor expression levels into fluorescent signals that can be detected by flow cytometry or sorting devices, simplifying the selection process while maintaining functionality enhancement.
Solution Approach 2:
The patent replaces manual or simple mechanical cell separation methods with fluorescence-activated cell sorting (FACS) technology. By substituting mechanical sorting with fluorescence-based identification and sorting, the system achieves precise selection of T cells based on receptor expression levels, enabling reliable enrichment of functional Tscm cells despite the increased complexity of the selection criteria.
3Reliability
If negative selection based on inhibitory receptor expression is performed, then highly functional T cells are obtained, but sorting precision requirements increase
Solution Approach 1:
The patent combines multiple fluorescent antibodies against different inhibitory receptors (PD-1, LAG-3, TIGIT, TIM-3) with standard T cell markers to create a composite sorting strategy. By using multiple markers in combination rather than relying on a single marker, the system achieves more precise identification and sorting of T cells with low overall inhibitory receptor expression, enhancing functional quality while managing sorting precision requirements through multi-parameter analysis.
Data Source
AI summary
The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm), in particular highly functional memory stem T-cells (Tscm) negatively selected on the basis of inhibitory receptor expression. This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.